dc.contributor.author |
Elera-Fitzcarrald, Claudia |
|
dc.contributor.author |
Reatégui-Sokolova, Cristina |
|
dc.contributor.author |
Gamboa-Cárdenas, Rocío V. |
|
dc.contributor.author |
Medina, Mariela |
|
dc.contributor.author |
Zevallos, Francisco |
|
dc.contributor.author |
Pimentel Quiroz, Víctor Roman |
|
dc.contributor.author |
Cucho-Venegas, Jorge M. |
|
dc.contributor.author |
Alfaro-Lozano, José L. |
|
dc.contributor.author |
Rodriguez-Bellido, Zoila |
|
dc.contributor.author |
Pastor-Asurza, César A. |
|
dc.contributor.author |
Perich-Campos, Risto |
|
dc.contributor.author |
Alarcón, Graciela S. |
|
dc.contributor.author |
Ugarte Gil, Manuel Francisco |
|
dc.date.accessioned |
2022-02-17T19:23:13Z |
|
dc.date.available |
2022-02-17T19:23:13Z |
|
dc.date.issued |
2022 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/11389 |
|
dc.description.abstract |
Objectives: This study aims to determine whether the MetS predicts damage accrual in SLE patients. Methods: This longitudinal study was conducted in a cohort of consecutive SLE patients seen since 2012 at one single Peruvian institution. Patients had a baseline visit and then follow-up visits every 6 months. Patients with ≥ 2 visits were included. Evaluations included interview, medical records review, physical examination, and laboratory tests. Damage accrual was ascertained with the SLICC/ACR damage index (SDI) and disease activity with the SLEDAI-2K. Univariable and multivariable Cox-regression survival models were carried out to determine the risk of developing new damage. The multivariable model was adjusted for age at diagnosis; disease duration; socioeconomic status; SLEDAI; baseline SDI; the Charlson Comorbidity Index; daily dose; and time of exposure of prednisone (PDN), antimalarials, and immunosuppressive drugs. Results: Two hundred and forty-nine patients were evaluated; 232 of them were women (93.2%). Their mean (SD) age at diagnosis was 35.8 (13.1) years; nearly all patients were Mestizo. Disease duration was 7.4 (6.6) years. The SLEDAI-2K was 5.2 (4.3) and the SDI, 0.9 (1.3). One hundred and eight patients (43.4%) had MetS at baseline. During follow-up, 116 (46.6%) patients accrued at least one new point in the SDI damage index. In multivariable analyses, the presence of MetS was a predictor of the development of new damage (HR: 1.54 (1.05–2.26); p < 0.029). Conclusions: The presence of MetS predicts the development of new damage in SLE patients, despite other well-known risk factors for such occurrence. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
SAGE Publications |
|
dc.relation.ispartofseries |
Lupus |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Metabolic Syndrome |
en_US |
dc.subject |
Lupus Erythematosus, Systemic |
en_US |
dc.subject |
Cohort Studies |
en_US |
dc.subject |
Hospital Guillermo Almenara Irigoyen |
en_US |
dc.title |
Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1177/09612033211061481 |
|
dc.relation.issn |
1477-0962 |
|